RGCC International

18/06/2026

Behind every breakthrough is a team driven by passion and perseverance.

Christine Wagner began her journey at as a Lab Technician and went on to build the Protein Biochemistry division from the ground up. Today, she leads an exceptional team at RGCC Central Europe, a testament to what dedication and opportunity can achieve together.

We’re proud to celebrate the people behind our science.

-

15/06/2026

Have you heard of our multi-cancer early detection test, Onco-D-Clare?

Early detection is one of the most important factors in improving cancer outcomes. That is why scientists developed Onco-D-Clare, an advanced cancer screening blood test designed to identify early biological changes linked to development, based on each individual’s genetic profile, even before symptoms appear.

📖 The test is supported by scientific evidence demonstrating that PBMC gene-expression profiling can distinguish between normal and cancer-related samples. Read the study here: https://eu1.hubs.ly/H0vzDRw0

👉 Learn more about the test: https://eu1.hubs.ly/H0vzCqc0

10/06/2026

📄 New publication from our research team

How long can a cancer cell line be cultured before its gene expression starts to drift, and why does it matter for research?

Our scientists at Central Europe investigated exactly that. By tracking the transcriptomic profile of HCT-116 colon cancer cells over 25 passages (~16 weeks), they found that gene expression remained largely stable up to passage 15. Beyond that point, genes linked to cell proliferation and cell death began to shift - changes that could affect how cells respond to therapies and compromise experimental reproducibility.

The takeaway: passage number is not a minor detail. It's a variable that can fundamentally influence research outcomes.

This work reinforces our commitment to rigorous, reproducible science and to understanding biology at the molecular level.

🔗 Read the full open-access article:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

01/06/2026

The Oncocount test is designed for patients diagnosed with cancer who wish to monitor the effectiveness of their ongoing treatment. It can also support early detection of recurrence for those in remission, helping patients and practitioners stay informed every step of the way.

🌱 Read more patient stories: rgcc-international.com/testimonials

27/05/2026

As Cancer Awareness Month comes to a close, it’s a great time to stay informed and take a closer look at the facts that matter. Learn more about skin , including its different types, stages, and available treatment options, in our patient guide.

📑Read it here: https://rgcc-international.com/patient-information/skin-cancer-treatment

-

Our experts explain the latest procedures for treating different skin cancer types and the role of new personalized approaches.

20/05/2026

How are healthcare practitioners using RGCC testing in clinical practice?

In this short clip, Dr. Neal Speight shares his experience using RGCC’s liquid biopsy and precision oncology tests to support more personalized cancer care and patient monitoring.

🎥 Watch the full interview on our YouTube channel to hear his complete insights and clinical perspective >> youtube.com/watch?v=vP7YkERV4g0

18/05/2026

RGCC’s Customer Relationship Manager, Gabriela Kranauer, participated in the “SSAAMP Jahreskongress 2026 – Universum Mensch und Gesundheit,” organized by the Swiss Society for Antiaging and Prevention and held in Zurich, Switzerland on May 16, 2026.

The congress brought together healthcare professionals and industry experts to discuss the latest developments in integrative and preventive medicine. Topics included longevity, long COVID, chronomedicine, and emerging supportive approaches in cancer care.

Events such as SSAAMP provide valuable opportunities to exchange knowledge, explore new scientific perspectives, and stay connected with ongoing advancements in healthcare and patient-centered care.

14/05/2026

We’re proud to showcase the certifications held by laboratories, reflecting our ongoing commitment to the highest standards of quality, safety, and reliability! From IAS Accreditation Testing to ISO certifications and recognitions from esteemed organizations like the College of American Pathologists and Swissmedic, our dedication to excellence is at the core of everything we do.

🏆 Check out the full details of our certifications on our website >> rgcc-international.com/

11/05/2026

Our dedicated scientific team is continuously uncovering new discoveries, delving into genetics, physiology, and different immune profiles.
🧫 Dive into our latest peer-reviewed research articles and abstracts to stay on top of the latest insights and discoveries: rgcc-international.com/published-articles/

07/05/2026

Our test provides a comprehensive overview of the Circulating Cells (CTCs) in a patient’s body by providing the following information:

🧬 A CTC count
🧬 A genetic and physiological expression profile of the cells
🧬 The effectiveness of 90+ chemotherapeutic agents and targeted therapies on the patient’s cancer cells
🧬 The resistance factor of the cancer cells

Learn more about the test >> rgcc-international.com/tests/onconomics/